Tag: FibroGen

March 26, 2019

7 Potential Blockbuster Drugs Investors Should Watch for in 2019

A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...
December 30, 2018

5 Top Weekly NASDAQ Biotech Stocks: Dova Up 41 Percent

Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.
December 20, 2018

FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat

FibroGen (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor...
June 7, 2018

FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat

FibroGen (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S....
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.